GENELUX CORPORATION Operating Lease, Right-of-Use Asset, Amortization Expense
GENELUX CORPORATION (GNLX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $170.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-13
- GENELUX CORPORATION operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $81.00K, a 1.25% increase year-over-year.
- GENELUX CORPORATION operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $89.00K, a 11.25% increase year-over-year.
- GENELUX CORPORATION operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $80.00K, a 51.81% decline year-over-year.
- GENELUX CORPORATION operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $80.00K, a 51.22% decline year-over-year.
- GENELUX CORPORATION operating lease, right-of-use asset, amortization expense for fiscal 2024 was $668.00K, a 28.71% increase from fiscal 2023.
- GENELUX CORPORATION operating lease, right-of-use asset, amortization expense for fiscal 2023 was $519.00K, a 25.06% increase from fiscal 2022.
- GENELUX CORPORATION operating lease, right-of-use asset, amortization expense for fiscal 2022 was $415.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $170.00K 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $89.00K 10-Q · filed 2026-05-07 | |||
| 2025-06-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $160.00K 10-Q · filed 2026-08-13 | $330.00K derived: sum of 3 quarters · filed 2026-08-13 | $498.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $80.00K 10-Q · filed 2026-05-07 | $250.00K derived: sum of 2 quarters · filed 2026-05-07 | $418.00K derived: sum of 3 quarters · filed 2026-05-07 | $584.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $170.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $338.00K derived: sum of 2 quarters · filed 2025-03-28 | $504.00K derived: sum of 3 quarters · filed 2025-03-28 | $668.00K 10-K · filed 2025-03-28 |
| 2024-09-30 | $168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $334.00K derived: sum of 2 quarters · filed 2024-11-14 | $498.00K 10-Q · filed 2024-11-14 | $604.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-06-30 | $166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $330.00K 10-Q · filed 2024-08-14 | $436.00K derived: sum of 3 quarters · filed 2025-05-06 | $575.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-03-31 | $164.00K 10-Q · filed 2025-05-06 | $270.00K derived: sum of 2 quarters · filed 2025-05-06 | $409.00K derived: sum of 3 quarters · filed 2025-05-06 | $565.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $245.00K derived: sum of 2 quarters · filed 2025-03-28 | $401.00K derived: sum of 3 quarters · filed 2025-03-28 | $519.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $139.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $295.00K derived: sum of 2 quarters · filed 2024-11-14 | $413.00K 10-Q · filed 2024-11-14 | $519.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $156.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $274.00K 10-Q · filed 2024-08-14 | $380.00K derived: sum of 3 quarters · filed 2024-08-14 | $484.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $118.00K 10-Q · filed 2024-05-09 | $224.00K derived: sum of 2 quarters · filed 2024-05-09 | $328.00K derived: sum of 3 quarters · filed 2024-05-09 | $431.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $210.00K derived: sum of 2 quarters · filed 2024-03-29 | $313.00K derived: sum of 3 quarters · filed 2024-03-29 | $415.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $207.00K derived: sum of 2 quarters · filed 2023-11-14 | $309.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $103.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $205.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $102.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |